Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
- Authors
- Kang, Byung Woog; Sohn, Sang Kyun; Moon, Joon Ho; Chae, Yee Soo; Kim, Jong Gwang; Lee, Soo Jung; Kim, Won Seog; Lee, Je-Jung; Lee, Se Ryeon; Park, Keon Uk; Lee, Ho Sup; Lee, Won Sik; Won, Jong-Ho; Park, Moo-Rim; Kwak, Jae-Yong; Kim, Min Kyoung; Kim, Hyo Jung; Oh, Sung Yong; Kang, Hye Jin; Suh, Cheolwon
- Issue Date
- Mar-2014
- Publisher
- 대한혈액학회
- Keywords
- Mantle cell lymphoma; Epidemiology; Trend; Survival; Chemotherapy; Rituximab
- Citation
- Blood Research, v.49, no.1, pp 15 - 21
- Pages
- 7
- Journal Title
- Blood Research
- Volume
- 49
- Number
- 1
- Start Page
- 15
- End Page
- 21
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12415
- DOI
- 10.5045/br.2014.49.1.15
- ISSN
- 2287-979X
2288-0011
- Abstract
- Background We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high-or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.